Lymphocyte blastogenesis and interferon production were measured in adult human leukocyte cultures stimulated with purified or crude cytomegalovirus antigens. Leukocytes from seropositive adults underwent blastogenesis when stimulated with purified or crude Towne strain antigen, whereas neither antigen stimulated blastogenesis in cultures from seronegative donors. The concentrations of antigens yielding maximal blastogenesis varied among the individuals tested. When cultures from seropositive individuals were stimulated with antigens prepared from three different CMV strains-AD-169, Towne, and Davis-comparable levels of blastogenesis were detected. Type 1 interferon was detected in supernatants of cultures stimulated with crude antigens regardless of the immune status of the donor. In contrast, when purified antigen was used as the stimulant, only cultures obtained from seropositive individuals produced detectable levels of interferon, which appeared to be predominantly type 2 or immune interferon.
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Assays for cytomegalovirus (CMV)-specific lymphocyte blastogenesis and interferon production have been used to measure cellular immune responses in CMV-infected individuals, including congenitally infected children and their mothers, and recipients of cardiac, bone marrow, or renal transplants (3, 5, 6, 11, 13, 14, 15, 18) .
In these studies a variety of CMV antigens were used, namely, sonicates or glycine extracts of infected fibroblasts, mitomycin-treated infected fibroblasts, or density gradient-purified virus. Leukocyte cultures were usually stimulated with a single concentration of antigen prepared from only one strain of CMV. The purpose of the present study was Interferon assay. Titrations of interferon were performed essentially as described by Paucker et al. (9) . Twofold serial dilutions of the supernatants of the leukocyte cultures were dispensed into microtiter wells in 0.1-ml volumes. Each well was then seeded with 0.1 ml of a suspension of 30,000 human foreskin fibroblasts (FS-4 strain), and the plates were incubated overnight at 370C in a 5% CO2 atmosphere. On the next day, the cultures were challenged with 0.05 ml of encephalomyocarditis virus at a multiplicity of infection of 0.25 and incubated for an additional day. The plates were then read for inhibition of cytopathic effect, and the titer was expressed as the reciprocal of the dilution protecting 50% of the cell sheet against challenge virus, corrected for a 1-ml volume. Virus, cell, and interferon controls, as well as human leukocyte interferon reference standard GO23-901-527, distributed by the Research Reference Reagents Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Md., were included in each titration. In this test, approximately eight interferon units correspond to one unit of the reference standard.
Characterization of interferon. Interferons produced in CMV-stimulated leukocyte cultures were tested for neutralization by sheep antibodies to human type 1 interferon prepared by repeated inoculations of a sheep as previously described (8) . Sendai virus-induced type 1 human interferon was kindly provided by Kari Cantell, State Serum Institute, Helsinki, Finland. Neutralizing titers of the serum against eight reference units of leukocyte and fibroblast type 1 interferons were 24,000/ml and 3,000/ml, respectively, whereas the antiserum was devoid of activity against eight units of type 2 interferon (neutralizing titer <25), provided by J. Georgiades, University of Texas Medical Branch, Galveston.
The neutralization assay was performed by adding 0.05-ml samples of leukocyte culture supernatants containing approximately eight units ofinterferon to equal volumes of twofold dilutions of the anti-type 1 serum.
The microplates containing the mixtures were incubated for 1 h at 37°C, after which foreskin fibroblasts were added. Subsequent procedures were as described for assays of interferon. The monolayers were challenged with encephalomyocarditis virus after 24 h of incubation, and viral cytopathic effect was read the next day. The reciprocal of highest dilution of antiserum which neutralized 8 U of interferon to the extent that 50% of the cell sheet showed cytopathic effect was considered the neutralizing titer.
Interferons detected in culture supernatants were also tested for pH stability (17) . Interferon samples were diluted in minimal essential medium containing 5% heat-inactivated fetal calf serum, to concentrations of 100 U of interferon per 0.1 ml. The untreated samples were stored at 4°C. The treated samples were dialyzed for 24 h at 4°C against pH 2 buffer and then returned to neutrality by dialysis against phosphatebuffered saline (pH 7.0) for 24 h at 4°C. Assays for interferon activity were then carried out as described above.
Complement-fixing antibodies to CMV. Complement-fixing antibody titers to CMV were kindly performed by Harvey Friedman, University of Pennsylvania School of Medicine, Philadelphia, as previously described (1).
RESULTS
Initial experiments were done to establish the doses of purified and crude CMV antigens which stimulated maximal lymphocyte blastogenesis and interferon production in 6-day cultures. When leukocytes from two seropositive individuals were incubated with varying doses of purified Towne antigen, lymphocyte blastogenesis was detected over a broad range of antigen concentration and was highest at final antigen dilutions of 1:80 or 1:320 (Table 1 ). The highest doses of antigen used stimulated the largest amounts of interferon production. With crude Towne antigen, highest blastogenesis was noted at final antigen concentrations of 1:20 and 1:80 in two donors (Table 2) . Interferon production was maximal with a final antigen dilution of 1:20 in the one case tested. Similar results with respect to antigen concentrations were obtained with AD-169 and Davis crude antigens (data not shown).
Since concentrations of antigens required for optimal blastogenesis varied among seropositive individuals, in subsequent experiments multiple dilutions of antigen were used, and the optimal response obtained was selected for analysis. Interferon was assayed only in supernatants of cultures incubated with 1:20 dilutions of antigens. Although other experiments indicated that higher levels of interferon were detected when the final antigen dilution was 1:5, the quantity of antigen required was not practical for routine lymphocyte blastogenesis and interferon production correlated with donor serological status. For these experiments leukocytes from six seronegative (complement-fixing titer <1:8) and eight seropositive adults were incubated with purified and, in some cases, crude Towne strain antigens as well as control antigens as described above. Lymphocytes from seropositive adults underwent blastogenesis when incubated with either antigen, whereas lymphocytes from seronegative individuals failed to respond (Fig. 1) .
Results of assays for interferon in supernatants of crude and purified Towne antigen-stimulated cultures are shown in Fig. 2 (Table 3) . Similar results were obtained when the control type 2 interferon was tested. In contrast, the interferon produced in crude antigen-stimulated cultures behaved like the type 1 interferon in that it was neutralized by antiserum to type 1 interferon and was stable at pH 2. Additional experiments were done to compare the responses of leukocytes from nine seropositive donors to antigens prepared from different strains of CMV. Interferon was not measured. The maximal blastogenic responses and the dilutions of Towne, AD-169, and Davis crude antigens which yielded such responses are shown in Table 4 . As in earlier experiments, the antigen concentrations required for maximal blastogenesis varied and there did not appear to be strainrelated antigen dosage requirements. Leuko- cytes from all ofthe individuals tested responded to all three antigens; however, there was some variability in the magnitude ofthe strain-specific responses. The mean blastogenic responses to Towne and AD-169 antigens were comparable, whereas the mean response to Davis was lower, but the difference was not statistically significant (P > 0.05).
DISCUSSION
In most published studies of CMV-specific lymphocyte blastogenesis single concentrations of CMV antigens were used to stimulate leukocyte cultures. However, antigen concentrations yielding maximal blastogenesis are not the same for all individuals, as shown in the present study and previously by Moller-Larsen et al. (7) and Pollard et al. (11) with different CMV antigen preparations. These results indicate that multiple concentrations of antigens should be used in clinical studies so that optimal responses can be obtained.
Whereas lymphocyte blastogenesis was frequently maximal when final antigen dilutions were greater than 1:20, interferon production was enhanced in the presence of high concentrations of antigen. No correlation existed between magnitude of blastogenesis and levels of interferon production in purified antigen-stimulated cultures. Different requirements for antigen and lack of correlation between these two responses suggest that they do not occur in concert with each other. It is indeed possible that different cell populations undergo blastogenesis and produce interferon, as has been recently described for herpes simplex virus-stimulated leukocyte cultures by Rasmussen and Merigan (12) . The lymphocyte blastogenesis assay described in the present study appeared to be specific since blastogenesis was detected only in leukocyte cultures from seropositive donors. Studies in which blastogenic responses to herpesvirus antigens including CMV correlated with the results of serological testing of the donors further document the specificity of blastogenesis assays in which herpesvirus antigens are used (7, 16, 21) .
Important differences were noted in interferon production elicited with purified and crude CMV antigens. Crude antigen stimulated type 1 interferon production in leukocyte cultures from both seronegative and seropositive donors as previously reported by Pollard et al. (11) . In contrast, interferon was detected in purified antigen-stimulated cultures only if the donor was seropositive, and the interferon detected appeared to be predominantly type 2 or immune interferon, although the possibility of the presence of small amounts of type 1 interferon cannot be completely excluded. Levin et al. reported that interferon produced in leukocyte cultures stimulated with glycine-extracted CMV antigen appeared to be a mixture of type 1 and type 2 interferon (5). Taken together, these results suggest that the type of interferon produced in CMV-stimulated leukocyte cultures may depend on the nature of the CMV antigen used. It was previously shown that the antigenic composition of interferon elicited in human diploid cells can be profoundly influenced by the nature of the inducing agent (4).
Evidence for antigenic heterogeneity among CMV strains has been obtained in neutralization assays most recently by Waner and Weller, who studied the kinetic neutralization of Towne, AD-169, and Davis strains of CMV using sera raised in rabbits (19) . Few data have appeared on the strain specificity of cell-mediated immune responses to CMV. In the present study all seropositive individuals responded to the three CMV antigens used, and the magnitudes of the mean responses were not significantly different. We have also shown that recipients of Towne strain CMV vaccine develop blastogenic responses to these same CMV antigens (Starr et 
